Hoth Therapeutics, Inc.
Index- P/E- EPS (ttm)-0.53 Insider Own2.73% Shs Outstand23.98M Perf Week-0.74%
Market Cap13.50M Forward P/E- EPS next Y-0.38 Insider Trans0.00% Shs Float23.32M Perf Month-4.62%
Income-12.60M PEG- EPS next Q-0.10 Inst Own8.30% Short Float0.50% Perf Quarter-40.03%
Sales- P/S- EPS this Y-10.10% Inst Trans3.21% Short Ratio0.03 Perf Half Y-39.94%
Book/sh0.33 P/B1.26 EPS next Y- ROA-95.00% Target Price3.00 Perf Year-74.38%
Cash/sh0.26 P/C1.63 EPS next 5Y- ROE-105.90% 52W Range0.38 - 1.75 Perf YTD-37.11%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-76.54% Beta1.02
Dividend %- Quick Ratio10.30 Sales past 5Y- Gross Margin- 52W Low8.05% ATR0.03
Employees4 Current Ratio10.30 Sales Q/Q- Oper. Margin- RSI (14)45.22 Volatility8.39% 7.78%
OptionableNo Debt/Eq0.00 EPS Q/Q55.50% Profit Margin- Rel Volume0.09 Prev Close0.41
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume4.05M Price0.41
Recom2.00 SMA20-0.92% SMA50-10.49% SMA200-44.30% Volume282,552 Change-1.06%
Oct-15-19Initiated The Benchmark Company Speculative Buy $10
Jun-29-22 01:25PM  
Jun-21-22 12:30PM  
Jun-15-22 12:30PM  
Jun-09-22 08:18AM  
May-06-22 09:02AM  
May-03-22 08:09AM  
Apr-19-22 03:29PM  
Apr-14-22 01:02PM  
Apr-12-22 08:17AM  
Apr-11-22 11:31PM  
Apr-01-22 08:02AM  
Mar-22-22 09:48AM  
Mar-11-22 08:00AM  
Feb-09-22 10:10AM  
Feb-07-22 08:02AM  
Jan-31-22 08:17AM  
Jan-05-22 05:18AM  
Jan-04-22 02:13PM  
Dec-21-21 07:59AM  
Dec-08-21 08:00AM  
Nov-30-21 08:00AM  
Nov-16-21 08:30AM  
Nov-08-21 08:38AM  
Oct-19-21 12:47PM  
Oct-12-21 10:04AM  
Sep-22-21 07:00AM  
Sep-21-21 10:05AM  
Sep-08-21 08:02AM  
Aug-11-21 09:01AM  
Aug-02-21 08:15AM  
Jul-13-21 10:13AM  
Jun-28-21 08:01AM  
Jun-13-21 11:23PM  
Jun-10-21 04:16AM  
Jun-07-21 02:31PM  
Jun-03-21 12:32PM  
Jun-01-21 08:05AM  
May-24-21 08:01AM  
May-13-21 08:28AM  
May-05-21 09:24AM  
May-03-21 09:13AM  
Apr-22-21 09:01AM  
Apr-20-21 09:06AM  
Apr-13-21 08:00AM  
Apr-12-21 09:15AM  
Apr-06-21 09:15AM  
Apr-05-21 08:01AM  
Mar-24-21 10:26AM  
Mar-23-21 08:01AM  
Mar-22-21 08:00AM  
Mar-19-21 07:00AM  
Mar-17-21 02:20PM  
Mar-11-21 09:15AM  
Mar-10-21 03:50PM  
Mar-08-21 05:00PM  
Mar-03-21 08:01AM  
Mar-01-21 03:02PM  
Feb-26-21 11:05AM  
Feb-25-21 09:55AM  
Feb-24-21 10:20AM  
Feb-23-21 08:02AM  
Feb-18-21 09:27AM  
Feb-17-21 09:00AM  
Feb-10-21 01:30PM  
Feb-09-21 08:00AM  
Feb-08-21 02:51PM  
Feb-02-21 08:45AM  
Jan-28-21 08:02AM  
Jan-27-21 08:31AM  
Jan-20-21 08:38AM  
Jan-13-21 08:01AM  
Jan-11-21 08:02AM  
Jan-05-21 09:00AM  
Jan-04-21 08:01AM  
Dec-31-20 08:01AM  
Dec-23-20 09:55AM  
Dec-21-20 08:30AM  
Dec-10-20 10:11AM  
Nov-16-20 11:30AM  
Nov-03-20 09:25AM  
Nov-02-20 10:16AM  
Oct-20-20 10:30AM  
Sep-24-20 08:38AM  
Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-003 to treat inflammatory bowel diseases, as well as acne and psoriasis; HT-004 for treatment of asthma and allergies using inhalational administration; HT-006 to treat lung diseases resulting from bacterial infections; and HT-002, a novel peptide for treating COVID-19. The company is also developing BioLexa Platform, a proprietary, patented, drug compound platform which is in phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus. The company has license agreements with the George Washington University; the University of Maryland; Isoprene Pharmaceuticals, Inc.; the North Carolina State University; Chelexa BioSciences, Inc.; Zylo Therapeutics, Inc., and the University of Cincinnati. It also has a research collaboration agreement with Weill Cornell Medicine to develop HT-003. Hoth Therapeutics, Inc. was incorporated in 2017 and is headquartered in New York, New York.